---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-017983"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:36:45.889678+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Femasys Q1 sales up 25.9% but net loss widens to $5.9M; cash runway only into early Q3 2025

## Summary
- Sales increased 25.9% YoY to $341K, driven by FemaSeed sales.
- Net loss widened to $5.9M ($0.23 per share) from $3.6M ($0.17) in prior year.
- R&D expenses surged 67.6% to $2.97M, mainly due to regulatory and development costs.
- Cash and equivalents $3.8M; company expects to fund operations only into early Q3 2025.
- FemBloc delivery system received CE mark recommendation in Europe; FemaSeed partnerships expanded.

## SEC filing metadata
- accession: 0001140361-25-017983
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036125017983/0001140361-25-017983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036125017983/ef20048606_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-017983
- JSON: https://secwatch.observer/filing/0001140361-25-017983.json
- Plain text: https://secwatch.observer/filing/0001140361-25-017983.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.